Imagine being told that a life-saving treatment exists, but it’s not available to you simply because of where you live. This is the harsh reality thousands of men in England have faced—until now. A groundbreaking prostate cancer drug, abiraterone, is finally set to be offered to thousands in England, marking a monumental shift in the fight against this devastating disease. But here’s where it gets controversial: despite its proven benefits, this drug has been available in Scotland and Wales since 2023, leaving English patients in the lurch. Why the delay? And what does this mean for those who’ve been waiting years for access?
Abiraterone, a drug that halts the spread of prostate cancer by cutting off the hormones it needs to grow, has been a lifeline for patients with advanced stages of the disease. Until now, it was only prescribed in England and Northern Ireland for the most severe cases. But in a matter of weeks, high-risk patients whose cancer hasn’t yet spread will gain access through the NHS—a move that could save hundreds of lives annually. Amy Rylance, from Prostate Cancer UK, hailed this as a ‘life-saving victory’ for the thousands of men who will now have a fighting chance.
And this is the part most people miss: the push for this change began with one man’s outrage. Giles Turner, diagnosed with aggressive prostate cancer in 2023, was shocked to learn that his postcode determined his access to abiraterone. While Scotland and Wales offered it freely, England did not. Determined to fight for fairness, Turner launched a campaign, even paying £250 a month out of pocket for the drug. ‘I felt fortunate to afford it, but outraged for those who couldn’t,’ he said. His efforts, alongside Prostate Cancer UK, finally paid off—but not without frustration. It took nearly three years for NHS England to act, despite evidence from the STAMPEDE trial in 2022 showing that abiraterone could halve the risk of cancer recurrence and reduce death rates by 40%.
So, why the holdup? The answer lies in bureaucracy and funding. For the medical regulator MHRA and the health watchdog NICE to approve expanded use, detailed applications are required—a time-consuming process. Plus, once abiraterone became a generic drug in 2022, pharmaceutical companies had little incentive to push for broader approval. Scotland and Wales found workarounds within existing protocols, but England lagged behind. NHS England now claims that savings from other medicines have freed up funds for this expansion. But is this enough to justify the years of delay? And what about Northern Ireland, where access remains uncertain?
Health Secretary Wes Streeting called this a ‘significant step’ that will give patients ‘precious extra years of life.’ But as we celebrate this progress, let’s not forget the systemic issues that allowed this disparity to persist. Is it fair that life-saving treatments should be rationed based on geography? And what more can be done to ensure equitable access to care across the UK? Let’s keep the conversation going—because every life saved is a victory, but every delay is a tragedy.
